Alligator Bioscience Logo
SE0024173637
A41BED

Alligator Bioscience

Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Alligator Bioscience stops Mitazalimab development, stock plunges 74%

    Alligator Bioscience’s board has halted further independent development of the CD40 antibody Mitazalimab due to the rapidly changing treatment landscape in pancreatic cancer and intends to out-license or sell the drug. Resources will be redirected to HLX22 (anti-HER2), which is being developed externally by Shanghai Henlius Biotech; Alligator will receive revenue participation for this without development expense. The company also announced a rights issue of around SEK 125.6 million and a bridge financing; cash of SEK 33 million will only last until mid-Q3 2026. The combination of the project halt, a heavily dilutive capital measure and strained liquidity triggered the sharp share price decline. » Mere på de.investing.com


  • Alligator Bioscience cuts costs sharply and plans phase‑III start for mitazalimab

    Alligator Bioscience reports significant cost reductions in Q1 2026 (annualized operating costs cut from 300 to 100 million SEK; Q1 costs 17 million SEK) and reports cash of 33 million SEK. Lead candidate mitazalimab showed a 30‑month survival rate of 20% in Phase II, and the company is preparing to start a Phase‑III trial in Q4 2026; a regulatory submission is expected in Q2 2026. Because cash is only expected to last until mid‑Q3 2026, Alligator is actively exploring financing options. The stock rose 4.69% following the results. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Alligator Bioscience en omsætning på 20,9 t € og et nettoresultat på -1,47 mio. €
(EUR) september 2026
YoY
Omsætning 20,9 t 50,63 %
Bruttofortjeneste -1,31 mio. -
Nettoresultat -1,47 mio. 32,53 %
EBITDA -1,72 mio. 155,43 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
41,96 t €
Antal aktier
53,09 mio.
Højeste/laveste i 52 uger
0,11 € - 0,000781 €
Udbytte Nej
Beta
1,17
P/E (PE Ratio)
-0,01
PEG (PEG Ratio)
0,00
K/I (PB Ratio)
0,24
P/S (PS Ratio)
1,65

Virksomhedsprofil

Navn
Alligator Bioscience
CEO
Søren Bregenholt
Medarbejdere 11
🍪

Parqet  bruger cookies. Læs mere